Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. This lack of consistency has made clinical trial design as well as understanding the potential market for therapies in SLE a unique challenge. To date, GlaxoSmithKline’s Benlysta (2011) is the only drug to have launched for SLE in over 50 years; however, its modest efficacy is a deterrent to uptake. Several therapies (i.e., anifrolumab, baricitinib, dapirolizumab pegol, voclosporin, obinutuzumab) in development for moderate to severe SLE without active renal disease and/or lupus nephritis are expected to fulfill the high unmet need for this condition. The Disease Landscape and Forecast provides detailed analyses of current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles facing emerging agents.
- How large is the treatable SLE population, and how will diagnosis / drug-treatment rates change over time?
- What is the current state of SLE treatment? What are the most important drugs for the treatment of patients without active renal disease and lupus nephritis, and why? What are interviewed experts’ insights into current treatment options? What are the key unmet needs in SLE?
- What are KOLs’ perceptions of key emerging therapies, and where do they see these agents fitting into the treatment algorithm? What sales / uptake could these agents secure in SLE? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Approximately 32 country-specific interviews with rheumatologists and nephrologists.
Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and LN).
Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.
Emerging therapies: Phase II: 19 drugs; Phase III: 6 drugs.
- Systemic Lupus Erythematosus - Landscape & Forecast - Disease Landscape & Forecast
Author(s): Ajay Puri, MBA; Sunali D. Goonesekera, SM
Ajay Puri is an Associate Analyst in the Immune and Inflammatory team at Decision Resources Group and works on indications like Ulcerative Colitis, Crohn’s disease, and Systemic Lupus Erythematosus.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA (Pharmaceutical) in marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Knowledge Management Associate (Oncology Vertical) at ZS Associates and worked on strategic projects such as competitive assessment, company and product profiling, conference coverage for clients, client specific newsletters and other business development initiatives.
Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.
Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.